Biblio
Melatonin Enhances the Anti-Tumor Effect of Fisetin by Inhibiting COX-2/iNOS and NF-κB/p300 Signaling Pathways. PLoS One. 2014;9(7):e99943.
Activator Protein-2β Promotes Tumor Growth and Predicts Poor Prognosis in Breast Cancer. Cell Physiol Biochem. 2018;47(5):1925-1935.
BPTF promotes hepatocellular carcinoma growth by modulating hTERT signaling and cancer stem cell traits. Redox Biol. 2018;20:427-441.
. Anti-αFR CAR-engineered NK-92 Cells Display Potent Cytotoxicity Against αFR-positive Ovarian Cancer. J Immunother. 2019.
Cleavage and polyadenylation specific factor 4 promotes colon cancer progression by transcriptionally activating hTERT. Biochim Biophys Acta Mol Cell Res. 2019.
Establishment of a hepatocellular carcinoma patient-derived xenograft platform and its application in biomarker identification. Int J Cancer. 2019.
Therapeutic potential of a TrkB agonistic antibody for ischemic brain injury. Neurobiol Dis. 2019.
. Antibacterial Fusion Protein BPI21/LL-37 Modification Enhances the Therapeutic Efficacy of hUC-MSCs in Sepsis. Mol Ther. 2020.
Aspirin enhances the sensitivity of colon cancer cells to cisplatin by abrogating the binding of NF-κB to the COX-2 promoter. Aging (Albany NY). 2020;12.
Bone marrow mesenchymal stem cell-derived exosomal miR-206 inhibits osteosarcoma progression by targeting TRA2B. Cancer Lett. 2020.
. Carcinogenetic initiation contributed by EpCAM+ cancer cells in orthotopic HCC models of immunocompetent and athymic mice. Oncotarget. 2020;11(22):2047-2060.
. Resolving the difference between left-sided and right-sided colorectal cancer by single-cell sequencing. JCI Insight. 2021.
. TRIP4 transcriptionally activates DDIT4 and subsequent mTOR signaling to promote glioma progression. Free Radic Biol Med. 2021.
BPTF inhibition antagonizes colorectal cancer progression by transcriptionally inactivating Cdc25A. Redox Biol. 2022;55:102418.
B2M is a biomarker associated with immune infiltration in High altitude pulmonary edema. Comb Chem High Throughput Screen. 2023.
B-cell prolymphocytic leukemia with P53 abnormalities successfully treated with bendamustine and rituximab: a report of three cases. Transl Cancer Res. 2023;12(7):1873-1882.
.